NewAmsterdam Pharma Co N.V.
NAMSNext catalyst
Obicetrapib
Atherosclerotic Cardiovascular Disease
Get an email about NAMS's next catalysts
Track NewAmsterdam Pharma Co (NAMS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout, regulatory event).See the timeline
3 upcoming, 1 past
obicetrapib + obicetrapib/evolocumab Phase 2 Est. Readout (VINCENT)
Primary completion for obicetrapib + obicetrapib/evolocumab trial (NCT06496243) in Dyslipidemias
SourceObicetrapib Phase 3 Est. Readout (PREVAIL)
Estimated primary completion for Obicetrapib trial (NCT05202509) in Atherosclerotic Cardiovascular Disease. Topline data typically follows completion by weeks to months.
SourceRegulatory — obicetrapib
NewAmsterdam Pharma announced regulatory decisions on obicetrapib and its fixed-dose combination with ezetimibe are expected in the second half of 2026 from EMA, UK, and Switzerland authorities, with potential launches by Menarini in Germany and the UK by 4Q26 pending positive outcomes.
SourceHow NAMS's past catalysts played out
Market Overview
Stock performance and key metrics
Monotherapy obicetrapib
Dyslipidemias
Obicetrapib
Dyslipidemias
obicetrapib + ezetimibe FDC
Lipidemia
obicetrapib + obicetrapib/evolocumab
Dyslipidemias
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Monotherapy obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib | Phase 3 | Dyslipidemias | - | - |
obicetrapib + ezetimibe FDC | Phase 3 | Lipidemia | - | - |
obicetrapib + obicetrapib/evolocumab | Phase 2 | Dyslipidemias | - | - |
Frequently asked questions
What is in NewAmsterdam Pharma Co N.V.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in NewAmsterdam Pharma Co N.V.'s (NAMS) pipeline across Phase 3, Phase 2. Its lead program is Obicetrapib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NewAmsterdam Pharma Co N.V.'s next FDA catalyst?→
NewAmsterdam Pharma Co N.V.'s (NAMS) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NAMS biotech catalysts?→
Add NAMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NewAmsterdam Pharma Co N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.